Display Settings:


Send to:

Choose Destination
N Biotechnol. 2011 Sep;28(5):511-7. doi: 10.1016/j.nbt.2011.03.020. Epub 2011 Apr 5.

Therapeutic applications of antibodies in non-infectious neurodegenerative diseases.

Author information

  • 1Department of Physiology and Neuroscience, New York University School of Medicine, 550 First Avenue, New York, NY 10016, United States. pavan.krishnamurthy@nyumc.org


Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease, Huntington's disease (HD) or amyotrophic lateral sclerosis (ALS) are all characterised histologically by the presence of deposits of misfolded proteins, tau and amyloid-β, α-synuclein, huntingtin or superoxide dismutase, respectively. Currently, these illnesses do not have any disease modifying treatment options. A novel therapeutic strategy that is being pursued is immunomodulation, which is using the body's immune system to target the self-proteins that are deposited. Most of these promising approaches are still in preclinical development while some have progressed to Phase III clinical trials. As new insights are gained, it is hoped that these immunotherapies will be effective tools at slowing the progression of these debilitating diseases.

Copyright © 2011 Elsevier B.V. All rights reserved.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk